• MariMed (MRMD) announced the evolution of its top-selling Betty’s Eddies all-natural cannabis fruit chews brand
  • The new product line includes some new products, some improved, and some long-time favourites that remain unchanged
  • It helps deliver specific effects, including sleep, relaxation, pain relief, heightened libido, and more
  • MariMed is a multi-state cannabis operator dedicated to improving lives through its high-quality products, its actions, and its values
  • MariMed Inc. (MRMD) opened trading at C$0.99 per share

MariMed (MRMD) announced the evolution of its top-selling Betty’s Eddies all-natural cannabis fruit chews brand.

The new product line includes some new products, some improved, and some long-time favourites that remain unchanged. All will feature a new look.

Each fast-acting fruit chew is custom-formulated using full-spectrum cannabis, supporting cannabinoids, and natural herbs, vitamins, and supplements. It helps deliver specific effects, including sleep, relaxation, pain relief, heightened libido, and more.

Betty’s Eddies fruit chew is vegan and gluten-free and handcrafted with real pieces of organic fruits and vegetables. It aims to deliver a delicious and sweet experience.

The new line-up of Betty’s Eddies fruit chews includes the following flavours, many with added benefits:

  • Bedtime Betty’s – for sleep
  • Ache Away Eddies – for pain relief
  • Take It Easy Eddies – for stress relief
  • Smashin’ Passion – for pleasure
  • Go Betty Go – for energy
  • Elderbetty – for immunity
  • Betty Good Times – for anytime

The evolution of Betty’s Eddies fruit chews addresses the needs of today’s cannabis consumers. According to industry research, consumers use cannabis edibles to achieve specific benefits. The top three benefits are: to sleep better, relax, and relieve pain.

MariMed is a multi-state cannabis operator dedicated to improving lives through its high-quality products, actions, and its values.

MariMed Inc. (MRMD) opened trading at C$0.99 per share.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.